New hope for tough blood cancers: experimental drug rebecsinib enters early trial
Disease control
Not yet recruiting
This early-phase study tests a new drug called rebecsinib in 28 people with two types of blood cancer: secondary acute myeloid leukemia (sAML) that has come back or not responded to treatment, or higher-risk myelofibrosis (MF). The goal is to find the safest and most effective do…
Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control
Last updated May 17, 2026 08:53 UTC